• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva Medical

Reva Medical’s Fantom bioresorbable, drug-eluting vascular scaffold succeeds at 6 months

September 20, 2017 By Sarah Faulkner

Reva Medical

As some companies have worked to improve drug-eluting stents by making them bioresorbable, some voices in the coronary intervention space have expressed concern over the rates of late stent thrombosis and repeat percutaneous coronary intervention seen with the devices. In a study published in the September issue of JACC: Cardiovascular Intervention, Reva Medical‘s (ASX:RVA) Fantom coronary […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: abbott, Reva Medical

Reva Medical pursues direct-sales after Boston Scientific distro negotiation deal lapses

August 4, 2017 By Fink Densford

Reva Medical, Boston Scientific

Reva Medical (ASX:RVA) said today it will take up direct marketing of its peripheral and vascular scaffolds after Boston Scientific‘s (NYSE:BSX) right to negotiate for exclusive distribution of the products expired. San Diego, Calif.-based Reva said that Boston Scientific had gained the right to negotiate for exclusive distribution rights under a 2007 agreement which would have positioned […]

Filed Under: Business/Financial News, Distribution, Stents Tagged With: Boston Scientific, Reva Medical

Reva closes $35m financing round

June 20, 2017 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) said today that it closed the 2nd tranche of its $34.6 million financing round. The company issued $47.1 million convertible notes, 2,119,500 options for the purchase of common stock and repurchased $12.5 million of its common stock from 1 unnamed investor. The San Diego, Calif.-based company’s 1st commercial product is its Fantom sirolimus-eluting […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Wall Street Beat Tagged With: Reva Medical

EuroPCR Roundup: Bioresorbable stents show promise, but metallic drug-eluting stents remain standard

May 22, 2017 By Sarah Faulkner

Updated to include a statement from an Abbott spokesperson.  Abbott‘s (NYSE:ABT) bioresorbable scaffold has been plagued with a myriad of troubling data, including a study that showed that the device is associated with an increase in thrombosis and target lesion failure. In April, Abbott restricted use of the Absorb devices to clinical registry studies. In response […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: Abbott Laboratories, amaranthmedical, Medtronic, Micell Technologies, Reva Medical, sveltemedicalsystem, xience

Reva plans $40m convertible note offering

April 25, 2017 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) said yesterday that it’s planning a $40 million convertible note offering with several institutional and 1 undisclosed corporate investor to fund the company’s ongoing needs, including the clinical development of its Fantom sirolimus-eluting bioresorbable coronary scaffold. Upon issuance of the convertible notes, the company is slated to receive $32.5 in net cash […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Funding Roundup, Vascular, Wall Street Beat Tagged With: Reva Medical

Reva Medical wins CE Mark for Fantom bioresorbable scaffold

April 4, 2017 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) said yesterday that it won CE Mark approval in the European Union for its Fantom sirolimus-eluting bioresorbable coronary scaffold. The Fantom scaffold is the San Diego, Calif.-based company’s 1st commercial product. Reva said it plans to begin selling the product in Europe this quarter. “CE Mark approval for Fantom is a major milestone for […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Regulatory/Compliance, Vascular, Wall Street Beat Tagged With: Abbott Laboratories, Biotronik, Elixir Medical Corporation, Reva Medical

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS